Drug Prices and Innovation

Politicians and even knowledgeable industry observers have called for price controls to deal with what many see as a crisis in drug pricing. Can pricing boards do what pharma and the market in the eyes of many have not: Balance patient needs for access with profits required to fund product development? If they fail, government controls could put at risk patients and an industry already facing an uncertain future. The answer depends on the relationship between prices and innovation.